Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELL | P14151 | 1/20 | 0.58 |
| ▸ | SELP | P16109 | 1/20 | 0.58 |
| ▸ | SELE | P16581 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | MPI | P34949 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.40 |
| ▸ | ERN1 | O75460 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12588326 | 0.88 | SELL (0.68) | SELLSELPSELEALDH1A1VRK1 | |
| SCHEMBL12217591 | 0.86 | ALDH1A1 (0.52) | SELLSELPSELEALDH1A1ACHE | |
| SCHEMBL13855810 | 0.82 | SELL (0.46) | SELLSELPSELEALDH1A1ACHE | |
| SCHEMBL4383630 | 0.82 | TTR (0.46) | SELLSELPSELEALDH1A1VRK1 | |
| SCHEMBL1942808 | 0.82 | ALDH1A1 (0.60) | SELLSELPSELEALDH1A1VRK1 | |
| SCHEMBL31062998 | 0.82 | SELL (0.46) | SELLSELPSELEALDH1A1ACHE | |
| SCHEMBL13855793 | 0.82 | SELL (0.46) | SELLSELPSELEALDH1A1ACHE | |
| SCHEMBL31716923 | 0.80 | SELL (0.44) | SELLSELPSELEALDH1A1VRK1 | |
| SCHEMBL24629320 | 0.78 | SELL (0.42) | SELLSELPSELEALDH1A1VRK1 | |
| SCHEMBL19439615 | 0.78 | CA1 (0.48) | SELLSELPSELECA2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2999788-B1 | RNA-DIRECTED DNA CLEAVAGE AND GENE EDITING BY CAS9 ENZYME FROM NEISSERIA MENINGITIDIS | UNIV NORTHWESTERN (US) | 2020-07-08 | — | — | EP | claimed |
| US-10385251-B2 | Compounds, complexes, compositions, methods and systems for heating and cooling | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-08-20 | — | — | US | claimed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| WO-2023239634-A2 | INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM | MICROBIOTIX, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOUTHERN RES INST (US) | 2023-09-14 | — | — | US | disclosed |
| US-11718593-B2 | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases | SOUTHERN RESEARCH INSTITUTE (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230242492-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20070259929-A1 | Therapeutic Compounds | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007127212-A2 | ANTI-VIRAL AGENTS THAT ACTIVATE RNASE L | THE CLEVELAND CLINIC FOUNDATION (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007095462-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-08-23 | — | — | WO | disclosed |
| EP-1820515-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20070043055-A1 | Dihydropteridinones in the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1256574-A1 | NITROGEN-CONTAINING COMPOUNDS HAVING KINASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | SELL 3744/4885SELP 3067/4885SELE 3533/4885 |
| US-11718593-B2 | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases | SMN1; SMN2, TDP2, TDP1 | SELL 2094/4885SELP 3334/4885SELE 2461/4885 |
| US-20070043055-A1 | Dihydropteridinones in the treatment of respiratory diseases | QDPR, DHPS, NDUFS6 | SELL 2776/4885SELP 1734/4885SELE 3773/4885 |
| US-20070259929-A1 | Therapeutic Compounds | PIGO, CYC1, COXFA4L2 | SELL 1293/4885SELP 947/4885SELE 1401/4885 |
| US-20230242492-A1 | THYROMIMETICS | TPO, TSHR, THOP1 | SELL 4856/4885SELP 4757/4885SELE 4310/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | SELL 2791/4885SELP 2346/4885SELE 2301/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | SELL 4596/4885SELP 4132/4885SELE 4542/4885 |
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | TNK2, ROCK1, ROCK2 | SELL 4718/4885SELP 4751/4885SELE 4699/4885 |
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, TDP2, TDP1 | SELL 2094/4885SELP 3334/4885SELE 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.